Skip to main content

Athenex, Inc 在 2019 年 11 月 7 日報告 2019 年第三季度的盈利業績

紐約洲水牛城, Oct. 24, 2019 (GLOBE NEWSWIRE) — Athenex, Inc. (Nasdaq: ATNX) 是一家致力於研究、開發和商業化治療癌症和相關疾病新療法的的全球生物製藥公司。其今天宣佈將在 2019 年 11 月 7 日(星期三)市場開放前,發佈於 2019 年 9 月 30 日結束的第三季度及九個月財務報表,且會於東岸時間早上 8 時提供現場電話會議和聲音網絡講解財務報告及提供業務近況。
若要參與本次會議,請在電話會議前十五分鐘致電 877-407-0784 (本地)或 201-689-8560 (國際),並提述會議驗証碼 13694941。 現場電話會議和聲音網絡重播都可以在公司網站的投資者關係頁面上取得,網址: http://ir.athenex.com/關於 Athenex, Inc.
創於 2003 年,Athenex, Inc. 是一家臨床階段的國際生物製藥公司,並致力成為研究、開發及商業化下一代癌症治療藥物的領導者。Athenex 下設三個平台,分別為腫瘤創新平台、商業平台和全球供應鏈平台。公司現有的臨床產品系列源自四個不同平台的科技:(1) 以非吸收 p-糖蛋白抑制劑為基礎的 Orascovery;(2)Src 酶抑制劑;(3) 受體工程化 T 細胞 (TCR-T) 及 (4) 消除精氨酸療法。Athenex 的員工遍佈全球,致力透過開發更有效及耐受的療法改善癌症病人的生活。Athenex 在紐約水牛城和克拉倫斯、新澤西州克蘭福德、德克薩斯州休斯頓、伊利諾伊州芝加哥、香港、台灣台北、中國重慶及英國曼徹斯特的多個地點均設有辦事處。如欲了解更多資訊,請瀏覽 www.athenex.com
聯絡
投資者關係:
Tim McCarthy
LifeSci Advisors, LLC 董事總經理
直線電話︰212-915-2564
Athenex, Inc.:
Randoll Sze
財務長
電郵:RandollSze@athenex.com
Jacqueline Li
企業發展與投資者關係
電郵:jacquelineli@athenex.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.